DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for small cell osteogenic sarcoma — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSmall cell osteogenic sarcoma maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for small cell osteogenic sarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) — ROS1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7Z5X · 2.035 Å · ligand (2R)-2-[5-(6-amino-5-{(1R)-1-[2-(1,3-dihydro-2H-1,2,3-triazol-2-yl)-5-fluorophenyl]ethoxy}pyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol (AWJ). Experimental structure, not a prediction.
What the evidence adds up to
In 1972, osteogenic sarcoma was described as a rare but virulent malignancy. Surgical amputation yielded 20% five-year survival. Radiation therapy alone gave 13%, and combined with surgery, 20%. The abstract noted that adriamycin and methotrexate had shown activity of a promising degree, but the efficacy of chemotherapy had not been fully evaluated. A study of 130 patients from 1975 reported an actual five-year survival rate of 25.5% (26 of 102 patients who had radical surgery). The therapeutic regimen at that time consisted of regional perfusion, amputation, bronchial artery infusion, and systemic administration of anticancer agents.
No abstract in this set specifically addresses small cell osteogenic sarcoma. The 1994 paper on small round cell sarcomas of bone and soft tissue treated 23 patients from 1968 to 1992 with adjuvant chemotherapy; 14 also received radiotherapy. Six of 20 patients who had surgery experienced local recurrence within one year. The overall survival rate for small round cell sarcomas of soft tissue was 15.6%, which was significantly lower than that of other high grade sarcomas. That paper did not separate osteogenic sarcoma from other small round cell tumours.
A 2008 editorial noted that sarcoma biology had been the foundation of understanding the molecular, immunologic, and viral bases of cancer, and that the retinoblastoma gene was linked to osteogenic sarcoma. It also stated that during the last quarter-century most investigators focused on liquid cancers and avoided solid tumours. No new treatment data were provided.
What is still missing is any dedicated trial for the small cell variant of osteogenic sarcoma. The historical survival figures come from mixed or broader sarcoma populations. No abstract reports a prospective trial stratified by histologic subtype, nor any modern targeted therapy or immunotherapy specifically tested in small cell osteogenic sarcoma. Funding for such a rare subtype, a trial design that can enrol enough patients, and molecular stratification to distinguish this variant from other small round cell sarcomas remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Surgical Oncology · 1972 · 276 citations
The therapy of osteogenic sarcoma: Current status and thoughts for the future
AbstractAbstract Osteogenic sarcoma is a rare but virulent malignancy for which significant prognostic factors have been identified. Evaluating the site, histology, size, and immunologic factors can help identify those patients at higher risk of recurrent disease. Surgical amputation is the mainstay of therapy for appropriate candidates (20% 5 year survivals). Radiation therapy alone yields 13%, and combined with surgery, 20% 5 year survivals. The efficacy of chemotherapy has not been fully evaluated but adriamycin and methotrexate have demonstrated activity of a promising degree. A protocol design to quickly and efficiently determine effective therapy for this disease could include pretherapeutic stratification, controlled trials of drugs or immune adjuvants with reevaluation at specific intervals of clinical significance.
Anticancer Research · 2016 · 55 citations · open access
Osteogenic Sarcoma: A 21st Century Review
AbstractCompared to other bone tumors, bone osteogenic sarcoma (BOS) continues to confer a much grimmer prognosis as the survival benefit of traditional chemotherapy treatment regimens is still unsatisfactory. Chemotherapy was demonstrated to be effective in eradicating both primary tumor and pulmonary metastases in the last century, with effective agents used in various combination regimens having changed the survival rate from less than 10% to 75%. The most common primary bone cancer, BOS is conventionally a primary intramedullary high-grade malignant tumor characterized by malignant cells forming immature bone or osteoid. BOS is a disease with diverse morphological presentations. The treatment of all morphological variants seem to have been the same for over 30 years. The introduction of antiproliferative agents such as insulin growth factor-binding protein 3 hold promise of a potentially veritable therapeutic target. In this review, we highlight recent data on osteosarcoma to consolidate a platform able to connect bench and bedside.
Journal of Bone and Joint Surgery · 1975 · 31 citations
Osteogenic sarcoma. A study of one hundred and thirty cases
AbstractOne hundred and thirty patients with osteogenic sarcoma were studied clinically, roentgenographically, and pathologically. Prognosis by each of ten factors was analyzed with the Wilcoxon test. The test yielded p smaller than 0.05 in a comparison between the survival curves of patients fifteen years old or younger and that of patients over fifteen, but other comparisons did not yield p smaller than 0.05. The actual five-year survival rate was 25.5 per cent (twenty-six of 102 patients who had radical surgery). Our therapeutic regimen for osteogenic sarcoma at the present time consists of regional perfusion, amputation, bronchial artery infusion, and systemic administration of anticancer agents.
Clinical Orthopaedics and Related Research · 2008 · 4 citations · open access
Editorial Comment: Cancer Biology – Lessons Learned From Sarcoma
AbstractSarcoma biology has been the foundation of our understanding the molecular, immunologic, and viral bases of cancer. In the premodern era of orthopaedics, before arthroplasty and arthroscopy, bone and soft tissue sarcoma research established basic concepts of cancer biology. Virtually every major advance in our understanding of how genetic code aberrations cause cancer originated in investigations of sarcoma. Retinoblastoma gene and osteogenic sarcoma Despite these contributions, during the last quarter-century most serious investigators focused on liquid (hematopoietic) cancers and eschewed the more difficult solid tumors.
Clinicopathological Study and Treatment for Small Round Cell Sarcomas.
AbstractWe treated 23 patients with small round cell sarcomas of bone and soft tissue from 1968-1992. All patients were treated with adjuvant chemotherapy and 14 (60.9%) also received radiotherapy. Six of 20 patients who received surgery, had local recurrences within one year. In this series, small round cell sarcomas occurred predominantly in the trunk (47.8%). Prognosis was evaluated by length of survival. The overall survival rate of small round cell sarcomas of soft tissue (15.6%) was significantly lower than that of other high grade sarcomas.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
